3.49
2.35%
0.08
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
8.45%
40.64
|
44.39 | 48.32 | 38.01 | 33.20 |
Operating Expenses
|
1.20%
54.88
|
54.23 | 53.23 | 53.99 | 46.47 |
Interest Income/Expense |
0.20%
7.032
|
7.018 | 6.847 | 6.528 | 6.216 |
Benefits Costs and Expenses |
100.00%
-
|
227.42 | - | - | - |
Costs And Expenses |
25.56%
54.88
|
73.72 | 53.23 | 53.99 | 46.47 |
Operating Income/Loss |
44.75%
-14.24
|
-9.841 | -4.913 | -15.98 | -13.28 |
Income/Loss From Continuing Operations Before Tax |
122.20%
40.64
|
-183.03 | 48.32 | -19.84 | -16.83 |
Income Tax Expense/Benefit, Deferred |
0.307
|
- | - | - | - |
Income Tax Expense/Benefit |
230.08%
0.307
|
-0.236 | -0.338 | -0.675 | - |
Income/Loss From Continuing Operations After Tax |
41.75%
-18.98
|
-13.39 | -12.19 | -19.84 | -16.83 |
Net Income/Loss
|
41.75%
-18.98
|
-13.39 | -12.19 | -19.84 | -16.83 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
92,554%
140.51
|
0.1517 | 138.06 | 137.34 | 137.14 |
Diluted Average Shares |
92,554%
140.51
|
0.1517 | 138.06 | 137.34 | 137.14 |
Basic Earnings Per Share |
55.56%
-0.14
|
-0.09 | -0.09 | -0.14 | -0.12 |
Diluted Earnings Per Share |
55.56%
-0.14
|
-0.09 | -0.09 | -0.14 | -0.12 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):